President Donald Trump’s team is rejecting former President Biden's plan to cover weight loss drugs like Wegovy and Zepbound for older Americans through Medicare. The Centers for Medicare and Medicaid ...

What they don't tell you about Ozempic Weight-loss drugs like Ozempic and Wegovy have helped millions of Americans lose ...

President Donald Trump’s administration has decided not to cover expensive, high-demand obesity treatments under the ...

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

The Trump administration has chosen not to finalize a rule proposed by the Biden administration that would have allowed ...

The Trump administration decided not to cover costly obesity treatments under Medicare's Part D. Despite a proposed rule by ...

The Biden administration proposal would have significantly expanded access to obesity to millions of Americans but would have cost the government billions.

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

The FDA's new rule restricting the sale of compounded semaglutide could make it more difficult for some people to obtain ...

Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk , nearly doubled annual income and investment ...

As semaglutide-based weight loss treatments such as Ozempic and Wegovy become more popular, new side effects are emerging – ...